Longitudinal contrast-enhanced cone beam breast computed tomography for monitoring treatment response in breast cancer neoadjuvant therapy: a comprehensive assessment [0.03%]
用于评估乳腺癌新辅助治疗疗效的纵向对比增强锥形束乳腺CT：全面评估
Yafei Wang,Yue Ma,Aidi Liu et al.
Yafei Wang et al.
Objectives: To validate cone-beam breast computed tomography (CBBCT) for evaluating NAT response using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and to explore correlations between multidimensiona...
Potential Loss of Imprinting of Tumor Suppressor Gene RB1 in Triple Negative Breast Cancer [0.03%]
三阴性乳腺癌中肿瘤抑制基因RB1印记的潜在丢失
Guojing Xie,Guangjie Zhang,Junhao Cui et al.
Guojing Xie et al.
Objectives: Triple negative breast cancer (TNBC) is an aggressive subtype with limitations in therapy. Although cyclin dependent kinase inhibitors (CDKi) have been proven in breast cancer, challenges remain in TNBC. Succe...
Incidence and risk factors for pneumonitis due to trastuzumab Deruxtecan in metastatic breast cancer: a retrospective cohort study [0.03%]
关于转移性乳腺癌患者接受德鲁替康治疗引起肺炎的发病率和危险因素的回顾队列研究
Maria Azhar,Felipe Soto,Amber Su et al.
Maria Azhar et al.
Background: Fam-trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) that targets human epidermal growth factor receptor 2 (HER2) and delivers a topoisomerase inhibitor payload. T-DXd has been effectively us...
Neighborhood deprivation, breast cancer outcomes and stress-related gene expression in leukocytes and tumor tissue [0.03%]
邻里贫困、乳腺癌预后与白细胞和肿瘤组织中应激相关基因表达的关系
Jie Shen,Yufan Guan,Joseph Boyle et al.
Jie Shen et al.
Background: Neighborhood socioeconomic deprivation is a recognized contributor to disparities in breast cancer outcomes, yet the biological mechanisms linking neighborhood context to tumor behavior remain poorly defined. ...
IL-3/STAT5/miR-155-5p axis supports stem-related pathway reprogramming in TNBC [0.03%]
IL-3/STAT5/miR-155-5p轴支持三阴性乳腺癌中干细胞相关通路的重编程
Alessandro Sarcinella,Sharad Kholia,Saveria Femminò et al.
Alessandro Sarcinella et al.
Background: Triple negative breast cancer (TNBC) remains one of the most aggressive subtypes of cancer with a poor prognosis and limited treatment options. Building on our previous findings of elevated Interleukin-3-Recep...
Differential prognostic significance of tumor size and node in invasive lobular carcinoma of breast [0.03%]
侵袭性乳腺小叶癌肿瘤大小及淋巴结分期的预后意义分析
Eunhye Kang,Ik Beom Shin,Ji-Jung Jung et al.
Eunhye Kang et al.
Background: Invasive lobular carcinoma (ILC) is the second most common histological type of breast cancer. Despite its distinct clinical and pathological characteristics, ILC shares the same prognostic classification syst...
Longitudinal changes in mammographic density and reproductive hormones during the menopausal transition in middle-aged Korean women: effect modification by obesity [0.03%]
中年韩国女性围绝经期乳房密度及生殖激素的纵向变化及其与肥胖的交互作用
Yoosun Cho,Yoonyoung Jang,Hee-Yeon Woo et al.
Yoosun Cho et al.
Background: Breast cancer, strongly associated with female hormones, peaks around perimenopause in Asia, versus post-menopause in Western countries. This study aims to investigate longitudinal changes in reproductive horm...
Lifestyle changes and postmenopausal breast cancer risk in women from the European Prospective Investigation into Cancer and Nutrition [0.03%]
欧洲癌症与营养前瞻性调查中的生活方式改变与绝经后妇女的乳腺癌风险关系研究
Fanélie Vasson,Komodo Matta,Carine Biessy et al.
Fanélie Vasson et al.
Background: The risk of breast cancer has been associated with various lifestyle factors, yet the evidence regarding how lifestyle modifications affect this risk remains limited. This study examines the relationship betwe...
Evaluating survival trends over time in patients with metastatic breast cancer and brain metastases: a single center retrospective cohort study [0.03%]
评估转移性乳腺癌合并脑转移患者生存趋势的单中心回顾队列研究
Nira A Krasnow,Michelle Jayaraj,Mia Salans et al.
Nira A Krasnow et al.
Background: Approximately 20–30% of patients with metastatic breast cancer (MBC) develop brain metastases (BM) over the course of their disease. It is critical to better understand risk factors and survival outcomes in t...
Pathological response and metabolites' prognostic role in HER2-positive breast cancer treated with neoadjuvant pyrotinib, trastuzumab, nab-paclitaxel, and carboplatin: a single-arm phase II trial [0.03%]
吡咯替尼新辅助治疗HER2阳性乳腺癌的病理缓解及代谢产物预后价值：单臂II期临床研究
Mei Liu,La Zou,Ningning Zhang et al.
Mei Liu et al.
Background: The trial aimed to evaluate the efficacy and safety of pyrotinib in combination with trastuzumab, nab-paclitaxel, and carboplatin (TCbHPy) in the neoadjuvant setting (ChiCTR2100043523), as well as the role of ...